Effects of desmopressin acetate on platelet aggregation, von Willebrand factor, and blood loss after cardiac surgery with extracorporeal circulation.

Andersson TL, Solem JO, Tengborn L, Vinge E

Circulation1 Mar 1990Cited by 32 (Europe PMC)

PMID2106402DOI10.1161/01.cir.81.3.872PepBankPUB-02106402

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialMechanism
In coronary bypass patients, the increase in factor VIII activity did not differ between desmopressin and placebo.
In plain wordsIn coronary bypass patients, the increase in factor VIII activity did not differ between desmopressin and placebo.
Peptide
Desmopressin
Outcome
No significant changeFactor VIII coagulant activity
Study
n = 19
Comparator
Placebo
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 microgram/kg body wt · intravenous infusion over 15 minutesAs given in this study (human).
Source sentences
Summary
The increase in factor VIII coagulant activity after infusion did not differ between the groups but there was a significantly larger increase in vWF:Ag levels in DDAVP-treated patients.
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of desmopressin acetate (DDAVP) on platelet aggregation and the von Willebrand factor antigen (vWF:Ag) were studied in 19 patients undergoing cardiac surgery with extracorporeal circulation.
Summary · context
The patients represented one of five blocks in a randomized double-blind placebo-controlled parallel group trial on the effects of DDAVP on postoperative bleeding after uncomplicated coronary artery bypass operations.
Summary · context
After termination of extra-corporeal circulation, DDAVP (0.3 microgram/kg body wt) or its vehicle was infused into a peripheral vein throughout 15 minutes.
Report a problemFND-0210640201
02HumanRandomized controlled trialMechanism
In coronary bypass patients, desmopressin produced a significantly larger increase in vWF antigen than placebo.
In plain wordsIn coronary bypass patients, desmopressin produced a significantly larger increase in a blood-clotting protein than placebo.
Peptide
Desmopressin
Outcome
Increasevon Willebrand factor antigen
Study
n = 19
Comparator
Placebo
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 microgram/kg body wt · intravenous infusion over 15 minutesAs given in this study (human).
Source sentences
Summary
The increase in factor VIII coagulant activity after infusion did not differ between the groups but there was a significantly larger increase in vWF:Ag levels in DDAVP-treated patients.
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of desmopressin acetate (DDAVP) on platelet aggregation and the von Willebrand factor antigen (vWF:Ag) were studied in 19 patients undergoing cardiac surgery with extracorporeal circulation.
Summary · context
The patients represented one of five blocks in a randomized double-blind placebo-controlled parallel group trial on the effects of DDAVP on postoperative bleeding after uncomplicated coronary artery bypass operations.
Summary · context
After termination of extra-corporeal circulation, DDAVP (0.3 microgram/kg body wt) or its vehicle was infused into a peripheral vein throughout 15 minutes.
Report a problemFND-0210640202
03HumanRandomized controlled trialMechanism
In coronary bypass patients, ADP-induced platelet aggregation was normal and did not differ significantly between desmopressin and placebo.
In plain wordsIn coronary bypass patients, platelet aggregation after ADP was normal and did not differ significantly between desmopressin and placebo.
Peptide
Desmopressin
Outcome
No significant changePlatelet aggregation response to ADP
Study
n = 19
Comparator
Placebo
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 microgram/kg body wt · intravenous infusion over 15 minutesAs given in this study (human).
Source sentences
Summary
The aggregatory response to adenosine-diphosphate (ADP) and ristocetin showed a normal pattern and was not significantly different between the two groups.
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of desmopressin acetate (DDAVP) on platelet aggregation and the von Willebrand factor antigen (vWF:Ag) were studied in 19 patients undergoing cardiac surgery with extracorporeal circulation.
Summary · context
The patients represented one of five blocks in a randomized double-blind placebo-controlled parallel group trial on the effects of DDAVP on postoperative bleeding after uncomplicated coronary artery bypass operations.
Summary · context
After termination of extra-corporeal circulation, DDAVP (0.3 microgram/kg body wt) or its vehicle was infused into a peripheral vein throughout 15 minutes.
Report a problemFND-0210640203
04HumanRandomized controlled trialMechanism
In coronary bypass patients, ristocetin-induced platelet aggregation was normal and did not differ significantly between desmopressin and placebo.
In plain wordsIn coronary bypass patients, platelet aggregation after ristocetin was normal and did not differ significantly between desmopressin and placebo.
Peptide
Desmopressin
Outcome
No significant changePlatelet aggregation response to ristocetin
Study
n = 19
Comparator
Placebo
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 microgram/kg body wt · intravenous infusion over 15 minutesAs given in this study (human).
Source sentences
Summary
The aggregatory response to adenosine-diphosphate (ADP) and ristocetin showed a normal pattern and was not significantly different between the two groups.
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of desmopressin acetate (DDAVP) on platelet aggregation and the von Willebrand factor antigen (vWF:Ag) were studied in 19 patients undergoing cardiac surgery with extracorporeal circulation.
Summary · context
The patients represented one of five blocks in a randomized double-blind placebo-controlled parallel group trial on the effects of DDAVP on postoperative bleeding after uncomplicated coronary artery bypass operations.
Summary · context
After termination of extra-corporeal circulation, DDAVP (0.3 microgram/kg body wt) or its vehicle was infused into a peripheral vein throughout 15 minutes.
Report a problemFND-0210640204
05HumanRandomized controlled trialEfficacy outcome
In coronary bypass patients, desmopressin did not decrease bleeding time compared with placebo.
In plain wordsIn coronary bypass patients, desmopressin did not decrease bleeding time compared with placebo.
Peptide
Desmopressin
Outcome
No significant changeBleeding time
Study
n = 19
Comparator
Placebo
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 microgram/kg body wt · intravenous infusion over 15 minutesAs given in this study (human).
Source sentences
Summary
As compared with placebo, DDAVP did not decrease the bleeding time or the postoperative blood loss.
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of desmopressin acetate (DDAVP) on platelet aggregation and the von Willebrand factor antigen (vWF:Ag) were studied in 19 patients undergoing cardiac surgery with extracorporeal circulation.
Summary · context
The patients represented one of five blocks in a randomized double-blind placebo-controlled parallel group trial on the effects of DDAVP on postoperative bleeding after uncomplicated coronary artery bypass operations.
Summary · context
After termination of extra-corporeal circulation, DDAVP (0.3 microgram/kg body wt) or its vehicle was infused into a peripheral vein throughout 15 minutes.
Report a problemFND-0210640205
06HumanRandomized controlled trialEfficacy outcome
In coronary bypass patients, desmopressin did not decrease postoperative blood loss compared with placebo.
In plain wordsIn coronary bypass patients, desmopressin did not decrease postoperative blood loss compared with placebo.
Peptide
Desmopressin
Outcome
No significant changePostoperative blood loss
Study
n = 19
Comparator
Placebo
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 microgram/kg body wt · intravenous infusion over 15 minutesAs given in this study (human).
Source sentences
Summary
As compared with placebo, DDAVP did not decrease the bleeding time or the postoperative blood loss.
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of desmopressin acetate (DDAVP) on platelet aggregation and the von Willebrand factor antigen (vWF:Ag) were studied in 19 patients undergoing cardiac surgery with extracorporeal circulation.
Summary · context
The patients represented one of five blocks in a randomized double-blind placebo-controlled parallel group trial on the effects of DDAVP on postoperative bleeding after uncomplicated coronary artery bypass operations.
Summary · context
After termination of extra-corporeal circulation, DDAVP (0.3 microgram/kg body wt) or its vehicle was infused into a peripheral vein throughout 15 minutes.
Report a problemFND-0210640206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.